X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NEC Bio collaborate with AGC Biologics to support the manufacturing and development of NECVAX-NEO1, which is being evaluated in the early-stage for treatingf solid tumors.
Lead Product(s): NECVAX-NEO1
Therapeutic Area: Oncology Product Name: NECVAX-NEO1
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: NEC Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 08, 2024
Details:
AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).
Lead Product(s): Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: Hu14.18K322A
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 11, 2024
Details:
Under the agreement, AGC Biologics is providing autologous production for MDG1015, a third generation TCR-T therapy, focused on the treatment of solid cancers, supporting Medigene’s IND filing and clinical trials.
Lead Product(s): MDG1015,PD1-41BB
Therapeutic Area: Oncology Product Name: MDG1015
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Medigene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 25, 2023
Details:
Under the agreement, AGC Biologics will assume a technology transfer and feasibility study for a drug product focused on the treatment of Idiopathic pulmonary fibrosis at the CDMO's center of Cell and Gene Excellence in Milan.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The Jikei University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2023
Details:
Under the agreement, AGC Biologics will manufacture TZIELD™ (teplizumab-mzwv), a new T1D treatment. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older.
Lead Product(s): Teplizumab-mzwv
Therapeutic Area: Endocrinology Product Name: Tzield
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Provention Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 24, 2023
Details:
Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Lead Product(s): VLP Peanut
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Recipient: Allergy Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Details:
Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Lead Product(s): VLP-Based Peanut Allergy Vaccine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Allergy Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Details:
AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech’s mRNA-based vaccine (BNT162b2) manufacturing process.
Lead Product(s): BNT162b2
Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b2
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 07, 2021
Details:
OCS-02 is a tumor necrosis factor-alpha (TNF alpha) inhibitor. TNF alpha is a proven biological target in ocular inflammation with possible dual actions: anti-inflammation and anti-necrosis.
Lead Product(s): OCS-02
Therapeutic Area: Ophthalmology Product Name: OCS-02
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Oculis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 06, 2021
Details:
Through the expanded partnership, AGC Biologics will bolster the security of supply of Rocket Pharmaceuticals across their entire lentiviral vector (LVV) pipeline, with the manufacture of LVV, which includes RP-L102 genetically modified with a lentiviral vector.
Lead Product(s): RP-L102
Therapeutic Area: Rare Diseases and Disorders Product Name: RP-L102
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Rocket Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
